Incyclinide
Systematic (IUPAC) name | |
---|---|
(4aS,5aR,12aS)-3,10,12,12a-Tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydronaphthacen-2-carboxamide | |
Clinical data | |
Trade names | Metastat (proposed) |
Legal status |
|
Identifiers | |
CAS Number | 15866-90-7 |
ATC code | None |
PubChem | CID 54678924 |
ChemSpider | 28530521 |
UNII | 21G64WZQ4I |
KEGG | D04519 |
ChEMBL | CHEMBL2104970 |
Chemical data | |
Formula | C19H17NO7 |
Molar mass | 371.35 g·mol−1 |
| |
|
Incyclinide (proposed trade name Metastat) is a chemically modified tetracycline antibiotic that was investigated in clinical trials for the treatment of rosacea,[1] various tumours, allergic and inflammatory diseases and a number of other conditions. The drug has no antibiotic properties.[2][3][4]
Mechanism of action
Like other tetracyclines, incyclinide inhibits matrix metalloproteinases.[2]
References
- ↑ Reuters: CollaGenex says incyclinide ineffective for rosacea
- 1 2 Viera, MH, Perez, OA, Berman, B. "Incyclinide". Drugs of the Future 32 (3): 209–214.
- ↑ H. Spreitzer (2 July 2007). "Neue Wirkstoffe - Incyclinid". Österreichische Apothekerzeitung (in German) (14/2007): 655.
- ↑ ClinicalTrials.gov: Incyclinide
This article is issued from Wikipedia - version of the Sunday, October 18, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.